Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors
AssigneeMedshine Discovery Inc.
InventorsKevin X Chen, Zhaoguo Chen, Li Zhang, Yanxin Yu, Kai Zhou, Boyu Hu, Xiaofei Wang, Guoping Hu, Jian Li, Shuhui Chen
Life of this patent
Estimating the term…
Abstract
Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.
Claims20
A compound represented by formula (IV), a pharmaceutically acceptable salt thereof or an isomer thereof,
- wherein,
- R1 is H;
- R2 is Me;
- alternatively, R1, R2 and the N atom on the morpholine ring form a 5-6 membered heterocycloalkyl;
- R3 is selected from NH2,
- 5-6 membered heteroaryl and C3-6 cycloalkyl-NH—C(═O)—, wherein the NH2,
- 5-6 membered heteroaryl and C3-6 cycloalkyl-NH—C(═O)— are optionally substituted by R, and the number of R is 1, 2 or 3;
- n is selected from 1 and 2;
- ring A is selected from phenyl and 6-10 membered heteroaryl;
- R4 is H;
- R5 is H;
- alternatively, R4 and R5 are linked together to form a 5-6 membered heterocycloalkyl;
- D1, D2, D3 and D4 are respectively selected from single bond, —CH2—, —CH2CH2— and —O—, and at least one of D1, D2, D3 and D4 is not a single bond, wherein the —CH2— or —CH2CH2— is optionally substituted by R, and the number of R is 1 or 2;
- D5, D6, D7 and D8 are respectively selected from a single bond, —CH2—, —O— and —NH—, and at least one of D5, D6, D7 and D8 is not a single bond, wherein the —CH2— is optionally substituted by R, and the number of R is 1 or 2, —NH— is optionally substituted by R;
- T1 is selected from CH and N;
- T2 is selected from —CH2—, —NH—, —O—,
- —S— and —C(═O)NH—, wherein the —CH2— is optionally substituted by R, and the number of R is 1 or 2, —NH— is optionally substituted by R;
- R is respectively selected from CF3, F, Cl, Br, I, OH, NH2, C1-3 alkyl, C1-3 alkoxy and C3-6 cycloalkyl, wherein the C1-3 alkyl, C1-3 alkoxy and C3-6 cycloalkyl are optionally substituted by R′, and the number of R′ is 1 or 2;
- R′ is respectively selected from F, Cl, Br, I, OH and NH2;
- the 5-6 membered heteroaryl and 6-10 membered heteroaryl respectively contain 1, 2 or 3 heteroatoms or heteroatom groups independently selected from —O—, —S—, —NH—, N, —C(═O)—, —C(═O)NH— and —C(═S) NH—.
A compound as shown below, a pharmaceutically acceptable salt thereof or an isomer thereof,
Dependencies are inferred from the claim text.